ELMD

Electromed is a genuinely high-quality niche business. Revenue has compounded from $35.8M (FY2021) to $64.0M (FY2025), with FY2025 up 17.0% and net income up 46.3% to $7.54M. The economics are excellent: 78.1% gross margin, 15.1% operating margin, 17.4% ROE, and $11.4M of operating cash flow on just $262K of capex. The balance sheet is pristine — $15.3M cash, liabilities/equity of only 0.25x, and essentially no meaningful debt (long-term debt was ~$1.1M as of the last tagged figure). Management is returning capital, spending $10.0M on buybacks and shrinking the share count 3.4%, which is why diluted EPS grew 46.6% — faster than net income. The single-product SmartVest HFCWO franchise is executing, and the FY2026 plan (four new sales territories, DTC/physician marketing, bronchiectasis clinical evidence) targets the largest, fastest-growing adult pulmonology segment.

The problem is price, not quality. At $45.43 the stock trades at 53.4x FY diluted EPS and 5.9x sales against ~17% revenue growth. The 46% earnings growth flatters the multiple: it is driven by operating leverage and buyback-aided EPS, neither of which repeats indefinitely, and once earnings growth normalizes toward the revenue rate, 53x looks demanding. You are paying a premium multiple for a durable but slow-lane compounder.